SPRY 8-K: SEC filing
ARS Pharmaceuticals
Filed with the SEC on · accession 0001193125-26-449748
SPRY filed a 8-K (current report) with the SEC on Nov 5, 2026. ARS Pharmaceuticals filed a routine Form 8-K cover page (document and entity information) dated November 5, 2026.
Summary of the filing
ARS Pharmaceuticals filed a routine Form 8-K cover page (document and entity information) dated November 5, 2026. The filing contains only administrative XBRL metadata and discloses no substantive corporate event.
Key details
✦ Ask GOAX AI about this filing — what it means for SPRY, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SPRY?
Click hereFrequently asked questions
What did SPRY file with the SEC on Nov 5, 2026?
SPRY filed a 8-K (SEC filing). ARS Pharmaceuticals filed a routine Form 8-K cover page (document and entity information) dated November 5, 2026. The filing contains only administrative XBRL metadata and discloses no substantive corporate event.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other SPRY SEC filings
Get alerts when SPRY files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days